TORC - resTORbio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

resTORbio, Inc.

500 Boylston Street
12th floor
Boston, MA 02116
United States

Full Time Employees21

Key Executives

NameTitlePayExercisedYear Born
Mr. Chen SchorCo-Founder, Pres, CEO & Director676.45kN/A1972
Dr. Joan Mannick M.D.Co-Founder & Chief Medical Officer509.06kN/A1959
Ms. Meredith ManningChief Commercial Officer393.08kN/A1972
Mr. John J. McCabe CPA, CPAVP of Fin.N/AN/A1968
Dr. Lloyd KlicksteinChief Scientific OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases primarily in the United States. Its lead program is targeting the selective inhibitor of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is an orally administered, TORC1 inhibitor, which completed Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as urinary tract infections, neurodegenerative diseases, and heart failure. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Corporate Governance

resTORbio, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.